List of works - Karen Willard-Gallo

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients

article

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

scientific article published on 22 February 2019

Breast cancer vaccines: Heeding the lessons of the past to guide a path forward

scientific article published on 29 November 2019

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

scientific article published on 17 June 2013

Cancer immunotherapy-associated hypophysitis

scientific article published on 01 June 2018

Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?

scientific article published on 14 July 2016

Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy

scientific article published on 10 October 2017

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers

scientific article published on 17 July 2017

FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders

scientific article published on 8 November 2016

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review

scientific article published on 02 January 2020

Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review

scientific article published on 01 February 2020

Immune evasion before tumour invasion in early lung squamous carcinogenesis

scientific article published on 26 June 2019

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis

scientific article published in 2022

Immunity drives TET1 regulation in cancer through NF-κB.

scientific article

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

article

Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

scientific article published on 10 December 2020

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

scientific article published on 20 August 2019

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

scientific article published on 12 May 2020

Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues

scientific article published on 01 January 2018

Quantitative fluorescence analysis of cyclosporine binding to human leukocytes ⬇️

scientific article published on 01 March 1984

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer

scientific article published on 16 June 2017

Significance of TIM3 expression in cancer: From biology to the clinic

scientific article published on 01 August 2019

Targeting PD-1 in cancer: Biological insights with a focus on breast cancer

scientific article published on 21 July 2019

The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History

scientific article published on 21 June 2019

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer

scientific article published on 13 August 2019

Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis

scientific article published on 01 October 2019

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

scientific article published on 14 December 2016

Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials